Founded in 2021 and headquartered in Nissequogue, New York, ProJenX is a clinical-stage biotech company that focuses on developing brain-penetrant therapies to treat neurodegenerative diseases, starting with ALS. The company's lead therapy candidate, prosetin, was developed through a research collaboration between Project ALS and Columbia University. ProJenX's patient-specific, cell-based discovery platform has the potential to create additional transformative neuroscience medicines.